BLTE - CIK 0001889109
The table below shows BELITE BIO, INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $45.38M | $29.94M | $24.84M | $8.87M | $7.42M | $3.69M |
| SG&A | $38.83M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $10.06M |
| $6.82M |
| - |
| - |
| - |
| Operating income | -$84.21M | -$40.00M | -$31.67M | -$12.82M | -$9.80M | -$5.74M |
| Income tax | $0.00 | $6.00K | $9.00K | - | - | $1.00K |
| Net income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| EPS (diluted) | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |